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Virus transmissiona b s t r a c t
Immediate vaccination of the most susceptible and epidemiological relevant animals is a crucial part of
control measures that facilitate virus elimination in case of entry of foot-and-mouth disease (FMD). The
objective of this study was to evaluate the effect of cattle vaccination 7 and 14 days prior challenge using
a vaccine commonly applied in systematic vaccination campaigns against transmission of FMD virus
(FMDV). Transmission of FMDV was investigated in three groups of ten cattle each: one non-
vaccinated group and two groups that were either vaccinated 7 days (7/vaccinated group) or 14 days
(14/vaccinated group) before intranasal (IN) inoculation. Five cattle heads from each group were inoc-
ulated using the IN-route with the A/Argentina/2001 FMDV strain, while the remaining five cattle heads
of each group were contact-exposed to inoculated cattle. Clinical signs were recorded; virus isolation and
genome detection by RT-PCR were carried out on oesophageal–pharyngeal fluid (OPF) and blood.
Neutralizing antibody titers and antibodies against non-structural proteins (NSP) of FMDV were also
determined. Results suggest that the experimental design, virus challenge dose, and virus infectivity were
appropriate and that the virus had been transmitted to naïve calves. Under the outlined experimental
conditions, vaccination 7 and 14 days prior to challenge induced full clinical protection against virus inoc-
ulation. Moreover, 7/ or 14/vaccinated calves that had been contact-exposed to 7/ or 14/vaccinated
IN-challenged calves, did not become infected. Consequently, no virus transmission occurred from vacci-
nated and subsequently infected calves to cohabitating vaccinated calves (R = 0). According to our results,
early vaccination during an outbreak is effective as virus transmission can be significantly reduced using
a vaccine commercially available, routinely applied in systematic vaccination campaigns.
 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Foot-and-mouth disease (FMD) is a highly contagious disease of
cloven-hoofed animals and considered the socioeconomic most
important disease of livestock. The maintenance of the FMD-free
status is a challenging task for countries free of FMD without and
with vaccination. Introduction of FMDV into several FMD-free
countries where vaccination is not practised caused severe epi-
demics (United Kingdom 2001, South Korea 2000–2002, amongothers). However, also FMD-free countries where vaccination is
practised, such as Argentina (2006), Brazil (2005), Paraguay
(2011), Colombia (2009–2017–2018), Republic of Korea (2010,
2014) and others, have experienced the introduction of FMDV
[1]. Thus, measures to avoid introduction of FMDV and exposure
of susceptible animals as well as establishment of early detection
systems and contingency plans are needed to control and prevent
outbreak of FMD.
The last FMD outbreak in Argentina was recorded in 2006 [1]
and currently the whole country holds the FMD-free status. Argen-
tina and other South American countries achieved FMD eradication
through control strategies essentially based on systematic and
mandatory vaccination of cattle. Although the overall cattle popu-
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groups of animals do exist such as calves with failure of passive
immune transfer and/or a not yet developed immunity (i.e. calves
that have not yet been vaccinated, or those that showed a poor
response to vaccination, etc.).
Immediate vaccination of most susceptible and epidemiologi-
cally relevant animals is a decisive part of control measures to
eliminate the virus in case of FMD-re-entry, if ‘‘vaccination to live”
policy is followed. The effect of vaccination on an animal involves
three aspects: (i) induction of protection against the disease (indi-
vidual immunity), (ii) reduction of susceptibility of an individual
animal (reduced infection risk), and (iii) reduction of infectivity
or horizontal transmission within a herd (herd immunity) [2,3].
It is of particular importance to understand the effect of emergency
vaccination on the reduction of virus transmission.
The transmission of FMDV between susceptible species at a
small-scale such as experimental studies and at higher-scales such
as between farms, countries and regions has recently been
reviewed [4,5]. The current contingency plan of Argentina foresees
that in case of an FMD-outbreak through reintroduction of strains
against which the current vaccine strains are effective, a commer-
cially available polyvalent immunogen will be applied. Accord-
ingly, in an event of disseminated outbreak, FMD-free countries
in which vaccination is not practiced may consider to acquire an
important volume of doses from countries that have stocks of
ready-to-use vaccines [6].
The effectiveness of a vaccine to prevent virus transmission
within a vaccinated population is determined best in homoge-
neous groups. This implies that all animals in a group should either
all be vaccinated or all be unvaccinated [2,7]. Accordingly, the
objective of this study was to evaluate the effect of cattle vaccina-
tion 7 and 14 days prior challenge using a commercial vaccine on
the transmission of FMDV. In this study, we set out to test the suit-
ability of a commercially available polyvalent vaccine, routinely
used for systematic vaccination campaigns, to reduce virus trans-
mission between vaccinated cattle.2. Materials and methods
2.1. Animals and experimental design
Thirty naïve Holando-Argentino breed male calves with an
average age of 216 days (range 210–225) and an average weight
of 205 kg, were used. The experimental protocol followed biosecu-
rity and animal welfare internal and federal regulations and was
approved by the Institutional Committee for the Use and Care of
Experimental Animals (CICUAE, CICVyA-INTA). Sample size of
experimental groups were estimated following a previous report
[8].
Fifteen days before challenge, animals were randomly allocated
into three groups following a simple randomization procedure.
Calves were vaccinated at the breeding farm 14 and 7 days
before challenge and assigned to the 14/vaccinated (n = 10) and
the 7/vaccinated (n = 10) group, respectively. Ten calves
remained non-vaccinated (non-vaccinated group). Animals were
transported to biocontainment animal facility 4 days before
challenge.
One day before challenge, five calves of each group were
assigned to be exposed by either intranasal or contact route
through a simple randomization process. At the day of challenge,
the five animals to be exposed by contact route from the 14/vac-
cinated, 7/vaccinated and non-vaccinated group were removed
from their pens and housed in three other separate rooms. The five
animals of each group that remained in the pen were challenged
via the intranasal (IN) route.Twenty-four hours after challenge, the initially separated ani-
mals were reunited with their original roommates and contact-
exposed to IN-inoculated calves until the end of the study at
28 days post inoculation (dpi). The duration of the experiment
was long enough for all susceptible animals to become infected
and of those infected to recover before the end of the study.
2.2. Vaccine and vaccination
A commercial vaccine (Bioaftogen, batch #688, Biogénesis
Bagó, Argentina) consisted in a water-in-oil single emulsion con-
taining the four FMDV strains O1 Campos, A24 Cruzeiro, A/Argen-
tina/2001, and C3 Indaial with an antigen concentration greater
than 30 mg per dose. The vaccine batch was examined by the
Argentina National Food Safety and Quality Service (SENASA) and
complied with requirements for safety, purity, and potency (in cat-
tle) before its release to the market [9,10]. The vaccine batch has
been approved with an expected percentage of protection (EPP)
of 96.3%, 95.7%, 98.0%, and 98.4% for O1 Campos, A24 Cruzeiro,
A/Argentina/2001, and C3 Indaial vaccine strains, respectively,
and has been applied in Argentine vaccination campaigns. Vaccina-
tion was performed using a single dose of 2 ml via the intramuscu-
lar route into the neck with 15-gauge, 18-mm needles on 10 ml
disposable syringes.
In Argentina, this vaccine is routinely administered following
local vaccination programme guidelines. The vaccination fre-
quency is twice a year in cattle younger than 2 years old and once
a year in those older than 2 years.
2.3. Virus challenge
Before challenge, calves were sedated using xylazine,
0.22 mg/kg, via the intramuscular route. Challenge was performed
via the IN-route, inoculating 10,000 TCID50% of A/Argentina/2001
FMDV strain per calf, in a volume of 1 ml per nostril. The A/
Argentina/2001 viral strain belongs to SENASA reference collection.
As inoculum the second cattle passage of a field isolate from
Trenque Lauquen, Buenos Aires province, Argentina obtained
during the 2001 outbreak was used [11]. The day of challenge
was defined as day 0 (0 dpi).
2.4. Clinical inspection and sampling
Clinical signs and rectal temperature were recorded daily from
0 to 14 dpi and later at 14, 21 and 28 dpi. Oesophageal-pharyngeal
fluid (OPF) and EDTA-anticoagulated blood samples were collected
at 0, 1, 3, 5, 7, 9, 11, 14, 21 and 28 dpi. Clotted blood for serology
was collected at 14, 7, 0, 7, 9, 14, and 28 dpi from animals of
all groups. Sera were separated and stored at 20 C until further
use. OPF sampling was carried out following the probang tech-
nique [12].
2.5. Virus isolation
Monolayers of BHK-21 in 96-well plates were used. OPF and
anticoagulated blood samples were inoculated in quadruplicate,
performing three passages of 48 h each, and examined for cyto-
pathic effect. The positive samples were titrated in tenfold serial
dilutions from undiluted to 10-6 dilution. The virus titers calculated
by the Reed and Muench Method [13] was expressed as
TCID50%/ml.
2.6. RNA extraction and real time RT-PCR (RT-PCR)
The procedures for RNA extraction and real time RT-PCR were
followed with minor modifications as described in the OIE
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or of an anticoagulated blood sample were mixed with 1000 ml
Trizol and RNA was extracted following the instruction of the
manufacturer. Viral RNA in samples was reverse transcribed
using random hexamers and then quantified by real-time RT-
PCR using primers targeting the 3D polymerase region [15].
The reaction was performed in a Roche Light Cycler 2.0 thermo-
cycler as previously described [16]. Samples that presented a
geometric increase in fluorescence emission in two successive
cycles prior to cycle number 40 were scored positive, and the
first of the two cycles showing emission elevation was consid-
ered to be the first cycle of positivity (CP). To convert cycle
threshold values generated by real time RT-PCR from experimen-
tal samples to RNA genome copies per milligram, serial 10-fold
dilutions of plasmid I38 containing the 3D sequence of FMDV
(kindly provided by Dr. Soledad Nuñez, Institute of Biotechnol-
ogy, INTA-Castelar) were analyzed as a quantitative positive con-
trol. The number of moles of RNA were calculated as = CP  -0.
25 + 11.68.2.7. Serology
Virus neutralization test (VNT) was carried out as described
previously [14], using BHK-21 cell suspensions and A/Argen-
tina/2001 virus.
Pre- and post-challenge serum samples were tested for the
presence of antibodies directed against the non-structural 3ABC
polypeptide of FMDV using two commercially available ELISA kits,
the PrioCHECK FMDV NS test [Prionics Lelystad, The Netherlands]
and the Screening Test NCPanaftosa-Bovine [PANAFTOSA, PAHO/
WHO, Rio de Janeiro, Brazil]. Additionally, serum samples collected
at 28 dpi were determined by the NCPanaftosa Confirmatory Test-
Bovine, which consisted in an enzyme-linked immunoelectrotrans-
fer blot [EITB] assay. Assays were performed as per manufacturer’s
instructions.2.8. Statistical analysis
We analyzed four indicators of infection in each group, and
applied statistical analysis to compare them [17]. The duration
of OPF virus excretion was estimated as the number of days from
the first to the last day the virus could be isolated from each ani-
mal until day 14 post infection. The mean daily virus detection
(MDVD) in OPF was estimated as the average of TCID50%/ml
per day in each group for the days the virus was detected. The
duration of viral genome detection in OPF was estimated as the
number of days from the first to the last day the viral genome
was detected by RT-PCR until day 14 post infection. The mean
daily viral genome detection (MDVGD) in OPF was estimated as
the average per day for the days viral RNA was detected by
RT-PCR.
Kruskal-Wallis test was used to analyze differences between
the three groups. When differences were statistically significant,
pairwise comparison between groups were performed (Statistix
8.0). When a comparison between two groups were required,
Wilcoxon rank sum test was applied (Statistix 8.0). A stochas-
tic susceptible-infectious-removed (SIR) model was used to esti-
mate the reproduction ratio R by maximum likelihood [8]. The
estimator of R was based on the final size of the outbreak
observed in the experiments. R is defined as the average number
of new cases of an infection. Comparison between R in
non-vaccinated and vaccinated calves was done by testing
that R is higher in vaccinated than in non-vaccinated calves
(one-tailed test) [8].3. Results
3.1. Clinical signs
All non-vaccinated calves that were IN-challenged or contact-
exposed developed generalized FMD (Table 1). In the group of
IN-challenged non-vaccinated animals, lesions compatible with
FMD were detected in the interdigital space, coronary band, ton-
gue, gums, and nostrils. All animals in this group showed severe
lesions in two or more of the above mentioned sites and fever
(>40 C) between 3 and 7 dpi. One of the 5 IN-challenged calves
evidenced lesions after 3 dpi and the remaining animals after 5
dpi (data not shown).
In the group of contact-exposed non-vaccinated calves, two ani-
mals presented lesions from 5 dpi, and three from 7 dpi on (data
not shown), and fever was detected between 5 and 9 dpi. One calf
died 11 dpi due to causes not related to FMD. In contrast, neither
IN-challenged nor contact-exposed vaccinated animals developed
clinical signs after challenge.3.2. Virus isolation
Virus in OPF was isolated from all IN-challenged calves with the
exception of one calf of the 7/vaccinated group (#715) (Table 1).
In contrast, among contact-exposed calves, virus was isolated only
from animals belonging to the non-vaccinated group (Tables 1, 3).
Regarding the number of days of virus detection (OPF), pairwise
comparisons among groups showed significant differences exclu-
sively between the IN-challenged non-vaccinated and the 7/vac-
cinated groups (P < 0.05). In addition, the MDVD was significantly
different only between the IN-challenged non-vaccinated group
(TCID50%/ml = 4.25) and the 7/vaccinated group (TCID50%/
ml = 1.95) (P < 0.05; Table 3).
Virus was isolated from blood from four IN-challenged animals
and from four animals of the contact-exposed non-vaccinated
calves (Table 1). In vaccinated groups, viremia was detected in a
single calf (#729) belonging to the14/vaccinated group subjected
to IN inoculation at 3 and 5 dpi.
Regarding the duration of virus detection and the MDVD in OPF
in unvaccinated calves, no significant differences (P > 0.05) were
found among calves exposed by contact to those IN-challenged
(Table 3).3.3. Real time RT-PCR
Viral genome was detected in OPF of all IN-challenged calves
and in the contact-exposed non-vaccinated calves, yet not in OPF
of contact-exposed calves that had been vaccinated (Table 2). No
significant differences were observed in the duration of viral gen-
ome detection in OPF among the IN-challenged 7/vaccinated,
14/vaccinated, and non-vaccinated group (P > 0.05; Table 3).
Regarding MDVGD in OPF, pairwise comparisons among groups
showed significant differences only between the IN-challenged
non-vaccinated (5.51) and the 7/vaccinated group (3.27)
(P < 0.05; Table 3). Regarding the duration of viral genome
detection and MDVGD in OPF in unvaccinated calves, no significant
differences (P > 0.05) were found between contact-exposed and
IN-challenged calf groups (Table 3).
In blood samples, viral genome could be detected from 4 out of
5 IN-challenged calves and contact-exposed calves of the non-
vaccinated groups (Table 2). Importantly, this result corresponds
with the detection of virus in blood sample in 4 out of 5 calves
in each non-vaccinated group (Table 1). Furthermore, as in the
detection of viremia, the viral genome was detected with delay
of one sampling in the in contact-exposed calves regarding the
Table 1
Virus isolation from oesofagueal-pharyngeal fluid (OPF) samples and blood, detection of viral RNA in OPF, clinical signs and antibodies to non-structural proteins (NSP).
1 – N = no clinical signs; clinical score was determined by the number of feet presenting FMD lesions plus the presence of lesions in the tongue, gum and nostrils; the
maximum score is 7. 2 – Detection of antibodies to NSP by PrioCHECK FMDV NS and Screening Test NCPanaftosa-Bovine.
NEG: non-reactive; the first number indicates the last day in which the sample was non-reactive and, the second number indicates the first day in which the sample was
reactive.
3 – TCID 50%/ml of FMDV detected in OPF test; * days after infection (dpi) in which virus was detected in blood; ** TCID 50%/ml of FMDV detected in blood.
Cells in gray indicate viral RNA detection by rt RT-PCR in OPF; for quantitative results refer to Table 2; y died at 11 dpi and has been non-reactive to NSP antibodies until 11
dpi.
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blood samples was detected until 7 dpi in the IN-challenged group
and until 11 dpi in the contact-exposed calf group.
Viral genome in blood was not detected in contact-exposed vac-
cinated animals. (Table 2). Regarding the IN-challenged vaccinated
calves no viral genome in blood was detected in the 7/vaccinated
group. However, 1 out of 5 animals presented viral genome in the
14/vaccinated group, consistent with virus isolation in blood on 3
and 5 dpi (#729, Table 1).
3.4. Serology
Vaccination induced in calves neutralizing antibodies to
A/Argentina/2001 FMDV as early as 7 dpv (Fig. 1). The vaccinated
and IN-challenged calves had a higher mean titer than vaccinated
and contact exposed calves from 7 dpi on at each bleeding time,
although observed differences were no significant (P > 0.05). The
kinetics of neutralizing antibodies of each group is shown in Fig. 1.
Regarding seroconversion to NSP antibodies, all IN-inoculated
cattle (with the exception of animal #715 of the 7/vaccinated
group) developed NSP antibodies. In non-vaccinated
IN-challenged and contact-exposed groups, NSP antibodies were
detected from 9 and 14 dpi, respectively, whereas in vaccinatedIN-challenged groups, NSP antibodies were detected from 14 dpi.
Vaccinated inoculated calves that scored positive showed T/C val-
ues between 1 and 2 by NCPanaftosa-Bovine (cut-off value T/C  1)
and PI values between 51 and 69% by PrioCHECK FMD NS (cut-off
value PI  50%), whereas non-vaccinated inoculated calves showed
T/C values above 2 by NCPanaftosa-Bovine and PI values above 70%
by PrioCHECK FMD NS (data not shown). Noteworthy, of non-
vaccinated calves challenged by contact, one calf died at day 11
dpi due to an undetermined cause not related to FMD. None of
the contact exposed 14 and 7/vaccinated groups developed
detectable antibodies to NSP at any time during the study (Table 1).
Results obtained by both ELISA kits were equivalent, with the
exception of animal #727 of the IN-challenge 7/vaccinated group
that showed reactivity to 3ABC only by PrioCHECK FMDV NS test at
28 dpi (PI value = 51%) and not by the other method.3.5. Viral transmission
All IN-challenged calves and all non-vaccinated calves that had
been contact-exposed became infected. Conversely, none of the
contact-exposed animals of-14/ and-7/vaccinated groups became
infected.
Table 2
Detection of viral RNA in oesofagueal-pharyngeal fluid samples and blood.
Days after challenge
0 1 3 5 7 9 11 14 21 28
Animal Group Calf # Viral exposure Blood OPF Blood OPF Blood OPF Blood OPF Blood OPF Blood OPF Blood OPF Blood OPF Blood OPF Blood OPF
Vaccinated 7 720 Contact – – – – – – – – – – – – – – – – – – – –
723 Contact – – – – – – – – – – – – – – – – – – – –
730 Contact – – – – – – – – – – – – – – – – – – – –
736 Contact – – – – – – – – – – – – – – – – – – – –
737 Contact – – – – – – – – – – – – – – – – – – – –
704 Intranasal – – – 4.77* – 2.28 – 3.01 – 2.77 – 1.72 – 1.11 – 1.81 – – – –
715 Intranasal – – – 1.11 – 1.11 – – – – – – – – – – – – – –
724 Intranasal – – 2.7 – – 1.76 – – – 1.91 – 1.11 – 1.11 – – – 1.11
727 Intranasal – – – 1.11 – 1.66 – 2.60 – 2.71 – 2.55 – 2.38 – 1.11 – – – 1.11
728 Intranasal – – – 2.45 – 1.11 – 2.70 – 2.6 – 2.46 – 2.49 – 1.11 – 1.11 – 1.11
Vaccinated 14 696 Contact – – – – – – – – – – – – – – – – – – – –
714 Contact – – – – – – – – – – – – – – – – – – – –
719 Contact – – – – – – – – – – – – – – – – – – – –
726 Contact – – – – – – – – – – – – – – – – – – – –
731 Contact – – – – – – – – – – – – – – – – – – – –
694 Intranasal – – – 2.60 – 3.19 – 4.02 – 1.11 – 2.62 – 3.13 – – – 1.67 – 1.11
705 Intranasal – – – 2.81 – 3.27 – 3.60 – 1.11 – – – 1.11 – – – 1.11 – –
729 Intranasal – – – 2.99 2.82 3.13 – 4.14 – 2.73 – 1.99 – 1.11 – 1.11 – – – –
732 Intranasal – – – 3.82 – 2.91 – 2.06 – 2.97 – 1.11 – 2.43 – 1.11 – – – 1.67
734 Intranasal – – – 3.35 – 3.12 – 1.99 – 2.21 – 2.26 – 2.25 – 2.40 – 1.11 – –
No vaccinated 699 Contact – – – – 1.11 – 5.69 3.37 5.77 1.11 5.3 – 5.31 – 2.53 – – – 2.17
701 Contact – – – – – – – 4.36 – 4.93 – 3.69 – 1.99 – – – 2.57 – –
702 Contact – – – – – – 2.24 5.82 4.49 4.47 – 4.33 1.11 3.47 – – – – – –
707 Contact – – – – 2.13 – 4.39 2.96 3.64 – 3.67 – 2.41 – – – – – –
712 Contact – – – – – 1.11 – 5.70 3.43 4.64 – 4.08 1.11 2.95 y y y y y y
693 Intranasal – – – 4.07 3.23 4.92 3.94 6.27 – 4.08 – 2.50 – 3.39 – – – – – –
703 Intranasal – – – 2.87 – 4.27 3.94 6.47 1.11 4.45 – 3.19 – 2.76 – – – – – –
706 Intranasal – – – 4.14 – 3.01 – 6.65 – 4.44 – 3.37 – 1.11 – – – – – 1.11
735 Intranasal – – – 2.88 2.83 3.39 3.95 5.07 – 4.27 – 2.09 – – – – 1.11 – –
738 Intranasal – – – 1.77 2.33 4.05 3.88 4.69 – 3.51 – 2.50 – 2.73 – – – – – –











Fig. 1. Mean virus neutralization test (VNT) antibody titers against A/Argentina/
2001 of 7/vaccinated group (A) and 14/vaccinated group (B) in comparison with
no-vaccinated group. Vertical lines indicate the standard error of the mean (SEM).
No significant differences were detected among groups (P > 0.05).
Table 3
Infection parameters and statistics1 applied for comparisons among experimental groups.
Intranasal Contact
Parameters (range 1–14 days post infection) 14/ vacc 7/ vacc Non-vaccinated 14/ vacc 7/ vacc Non-vaccinated
Duration of virus excretion in OPF (days) 9.2ab 13.3a 7.0b NVD NVD 6.8
Mean daily virus detection (MDVD) in OPF 2.90ab 1.95a 4.25b NVD NVD 4.06
Duration of viral genome detection in OPF 12.80a 12.20a 11.00a NGD NGD 9.2
Mean daily viral genome detection (MDVGD)2 in OPF (days) 3.20ab 3.27a 5.51b NGD NGD 5.16
NVD: no virus detected; NGD: no genome detected; different letters mean significant differences between groups challenged intranasally (P  0.05); there were no significant
differences in any indicator between animals challenged intranasally and by contact in the non-vaccinated group (P > 0.05).
1 Kruskal-Wallis test. Wilcoxon Rank sum test (comparison between two groups).
2 log10 copies of viral RNA/ml.
6 S. Duffy et al. / Vaccine: X 5 (2020) 100063The RNoVacc was estimated as1 (95% CI, 0.67-1), which is not
significantly > 1 (P = 0.083). For both groups, RVacc-14 and RVacc-7
was estimated to be 0 (95% CI, 0–2.18), which is not
significantly < 1 (P = 0.13). Comparison between RNoVacc and either
RVacc-14 or RVacc-7 showed a significant difference (P = 0.013).4. Discussion
The knowledge of the effect of vaccination to prevent virus
transmission is crucial for the design of control measures including
emergency vaccination and prediction of virus dissemination in an
event of an outbreak. Previous studies in cattle determined the
effectiveness of vaccination in inducing early protection [18,19].
Correspondingly, in our study, calves vaccinated either 7 or 14 days
prior to IN-inoculation were protected against clinical disease. Pre-
vious experiments also showed the capacity of vaccination in
reducing virus transmission in cattle [5].
The aim of our study was to provide additional data on FMDV
transmission among non-vaccinated and vaccinated calves usinga regular commercially available vaccine applied in vaccination
campaigns.
As expected, IN-inoculation of non-vaccinated calves with
FMDV induced clinical disease, shedding of FMDV, viremia, sero-
conversion to NSP, and generation of neutralizing antibodies indi-
cating successful inoculation. During the FMD outbreak in
Argentina in 2001, the A/Argentina/2001 strain showed a high
transmissibility within and between herds, and was therefore used
in this study for challenge. As infection parameters demonstrated,
IN-inoculated calves transmitted the virus to cohabitating naïve
calves (R = 1).
Duration of genome excretion in OPF was similar between IN-
challenged groups of non-vaccinated, 7/, and 14/vaccinated
calves, demonstrating the very high virus challenge doses applied
in our experiment. In comparison to virus isolation, duration of
genome detection in non-vaccinated animals was longer in the
IN-challenged than in the contact-exposed group, which may be
explained by the higher sensitivity of the RT-PCR assay as com-
pared to virus isolation. In overall, these data demonstrate that
the experimental design, challenge virus dose and virus infectivity
were appropriate and that virus transmission from naïve
IN-challenged calves to naïve calves took place.
One animal of the 7/vaccinated IN-challenged group (#728)
showed at 28 dpi virus detection in OPF and became ‘‘carrier”. This
situation is not unexpected as vaccination protects against clinical
signs, and a proportion of animals may remain subclinically
infected and turn into carriers [20].
The detection of viremia and viral genome in a single vaccinated
calf (#729, from the 14/vaccinated IN challenged group) has been
suggestive for low virus replication that did not lead to dissemina-
tion and development of vesicles in epithelial areas. This finding
may be explained by the fact that the animal #729 showed the
lowest neutralizing titer of this group on the day of challenge (data
not shown). Previous studies did not find virus in the blood of vac-
cinated inoculated cattle, even in the presence of virus or virus
genome in OPF samples [7,18,21]. This difference with regard to
our finding may be due to challenge methods, dose of challenge,
virulence of the strain of challenge, vaccine potency, among others.
Regarding seroconversion to NSP, it should be pointed out that
antibodies to NSP were detected later in IN-challenged vaccinated
groups (from 14 dpi) than in the IN-challenged non-vaccinated
group (from 9 dpi), along with lower ELISA values, probably due
to the effect of vaccination that limit viral replication [22]. Addi-
tionally, no NSP antibodies were detected in animal #727 from
7/vaccinated challenged group by NCPanaftosa-Bovine, but it
was found positive by PrioCHECK FMDV NS at 28 dpi. This late
detection of NSP antibodies in cattle in which virus was isolated
from OPF was not unexpected. The discrepancy in the NSP anti-
body detection between both tests may be explained by the bor-
derline result of this serum (PI value = 51%) in PrioCHECK FMDV
NS that resulted in a nonreactor by NCPanaftosa-Bovine test, fre-
quent finding in samples near the detection limit as the diagnostic
sensitivity reported by both tests was similar [22].
S. Duffy et al. / Vaccine: X 5 (2020) 100063 7Under the applied experimental conditions, vaccination 7 or
14 days prior to challenge induced full clinical protection against
IN virus inoculation. Moreover, 7/ or 14/vaccinated calves that
had been contact-exposed to-7/ or 14/vaccinated IN-inoculated
calves, did not become infected. Consequently, no virus transmis-
sion occurred from vaccinated and subsequently infected calves
to cohabitating vaccinated calves (R = 0).
The registered vaccine in Argentina is composed of 4 vaccine
strains, including C3 Indaial, as well as the vaccine authorized in
USA and Canada for emergency situation [6,23]. Although there
were no reports of serotype C in the world since 2004, the autho-
rized vaccine in Argentina requires the inclusion of serotype C
since 2006 [24]. Regarding potency, the vaccines manufactured
in Argentina are formulated to meet a minimum of 75% of EPP
(or minimum of 3 PD50). However, most of the batches released
to the market showed >85% of EPP in the potency test in cattle con-
ducted by SENASA [25]. Additionally, a commercial vaccine similar
to the one used in our study has shown early immunity in cattle
[26]. Unlike previous studies in cattle in which high-potency vacci-
nes were used [7,21,27], this study used a polyvalent vaccine that
is regularly administered in systematic vaccination campaigns in
Argentina. This has the added advantage that in case of an epi-
demic outbreak is faced, the vaccine would be rapidly available
in large quantities. In this sense, rolling stocks of ready-to-use
polyvalent vaccines have been considered as a feasible vaccine
reserve to respond rapidly to outbreaks [28]. Mostly, FMD free
countries have Antigen Banks through contracts with vaccine man-
ufacturing companies. In the case of disseminated outbreaks in
high density areas, the number of doses from Antigen Banks may
be insufficient, and therefore the use of ready-to-use vaccines from
countries that apply such vaccines in their vaccination programs
has been proposed [29]. In agreement with the results presented
in this controlled study, field evidence on the effects of vaccination
reducing within herd transmission was reported by Brito et al. [30]
in which the protective effect of the vaccine was evidenced by the
association between vaccination and low rate of within herd
transmission.
The full protection and the lack of virus transmission between
vaccinated calves at an early stage after vaccination, as observed
under the outlined experimental conditions, are key features for
effective contingency policies. According to our results, vaccination
seems to be a suitable measure to control an outbreak because it
has the potential to reduce significantly virus transmission under
the premise that the corresponding vaccine is rapidly applied.5. Conclusions
We studied the effect of vaccination on the transmission of
FMDV in cattle using a commercially available polyvalent vaccine.
Our work demonstrated that vaccination 7 and 14 days prior to
challenge induced full clinical protection against virus inoculation.
Additionally, the vaccinated calves that had been contact-exposed
to vaccinated and inoculated calves did not become infected. Thus,
no virus transmission occurred from vaccinated and subsequently
infected calves to cohabitating vaccinated calves.
According to our results, early vaccination during an outbreak is
effective as virus transmission can be significantly reduced using a
commercial polyvalent vaccine, routinely used in systematic vacci-
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